The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Open accessAbstract
BACKGROUND: Infection with human papillomavirus (HPV) and diseases caused by HPV are common in boys and men. We report on the safety of a quadrivalent vaccine (active against HPV types 6, 11, 16, and 18) and on its efficacy in preventing the development of external genital lesions and anogenital HPV infection in boys and men. METHODS: We enrolled 4065 healthy boys and men 16 to 26 years of age, from 18 countries in a randomized, placebo-controlled, double-blind trial. The primary efficacy objective was to show that the quadrivalent HPV vaccine reduced the incidence of external genital lesions related to HPV-6, 11, 16, or 18. Efficacy analyses were conducted in a per-protocol population, in which subjects received all three vaccinations and were negative for relevant HPV types at enrollment, and in an intention-to-treat population, in which subjects received vaccine or placebo, regardless of baseline HPV status. RESULTS: In the intention-to-treat population, 36 external genital lesions were seen in the vaccine group as compared with 89 in the placebo group, for an observed efficacy of 60.2% (95% confidence interval [CI], 40.8 to 73.8); the efficacy was 65.5% (95% CI, 45.8 to 78.6) for lesions related to HPV-6, 11, 16, or 18. In the per-protocol population, efficacy against lesions related to HPV-6, 11, 16, or 18 was 90.4% (95% CI, 69.2 to 98.1). Efficacy with respect to persistent infection with HPV-6, 11, 16, or 18 and detection of related DNA at any time was 47.8% (95% CI, 36.0 to 57.6) and 27.1% (95% CI, 16.6 to 36.3), respectively, in the intention-to-treat population and 85.6% (97.5% CI, 73.4 to 92.9) and 44.7% (95% CI, 31.5 to 55.6) in the per-protocol population. Injection-site pain was significantly more frequent among subjects receiving quadrivalent HPV vaccine than among those receiving placebo (57% vs. 51%, P<0.001). CONCLUSIONS: Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age. (Funded by Merck and others; ClinicalTrials.gov number, NCT00090285.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Self-citationVilla, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Self-citationBrown, D. R., Kjaer, S. K., Sigurdsson, K., Iversen, O., Hernandez‐Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Tay, E. H., Garcia, P., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597307 · Cited by 627
Self-citationPrevalence of HPV Infection among Men: A Systematic Review of the Literature
Dunne, E. F., Nielson, C. M., Stone, K. M., Markowitz, L. E., & Giuliano, A. R. (2006) · The Journal of Infectious Diseases · doi:10.1086/507432 · Cited by 615
Self-citationGiuliano, A. R., Lazcano-Ponce, E., Villa, L. L., Flores, R., Salmeron, J., Lee, J.-H., Papenfuss, M. R., Abrahamsen, M., Jolles, E., Nielson, C. M., et al. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0151 · Cited by 350
Self-citationPartridge, J. M., Hughes, J. P., Feng, Q., Winer, R. L., Weaver, B. A., Xi, L., Stern, M. E., Lee, S., O’Reilly, S. F., Hawes, S. E., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/521192 · Cited by 248
Wheeler, C. M., Kjaer, S. K., Sigurdsson, K., Iversen, O., Hernandez‐Avila, M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597309 · Cited by 242
Self-citationFairley, C. K., Hocking, J. S., Gurrin, L. C., Chen, M. Y., Donovan, B., & Bradshaw, C. S. (2009) · Sexually Transmitted Infections · doi:10.1136/sti.2009.037788 · Cited by 223
Seroprevalence of Human Papillomavirus Type 16 Infection in the United States
Stone, K. M., Karem, K. L., Sternberg, M. R., McQuillan, G. M., Poon, A. D., Unger, E. R., & Reeves, W. C. (2002) · The Journal of Infectious Diseases · doi:10.1086/344354 · Cited by 222
Cited by
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,638
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Self-citationPrevalence of Oral HPV Infection in the United States, 2009-2010
Gillison, M. L., Broutian, T., Pickard, R. K. L., Tong, Z.-Y., Xiao, W., Kahle, L., Graubard, B. I., & Chaturvedi, A. K. (2012) · JAMA · doi:10.1001/jama.2012.101 · Cited by 1,064
Carcinogenic human papillomavirus infection
Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.86 · Cited by 999
Jemal, A., Simard, E. P., Dorell, C., Noone, A.-M., Markowitz, L. E., Kohler, B., Eheman, C., Saraiya, M., Bandi, P., Saslow, D., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs491 · Cited by 993
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira, E. D., Aranda, C., Jessen, H., Hillman, R., Ferris, D., Coutlee, F., Stoler, M. H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010971 · Cited by 948
Self-citationUS Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
Saraiya, M., Unger, E. R., Thompson, T. D., Lynch, C. F., Hernandez, B. Y., Lyu, C. W., Steinau, M., Watson, M., Wilkinson, E. J., Hopenhayn, C., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv086 · Cited by 761
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
“Efficacy in males The efficacy of Gardasil® was examined in a placebo-controlled, double-blind trial in 4065 men ages 16–26 from 18 countries [51].”
BackgroundCancers with increasing incidence trends in the United States: 1999 through 2008
Simard, E. P., Ward, E. M., Siegel, R., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20141 · Cited by 724
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study
Giuliano, A. R., Lee, J.-H., Fulp, W., Villa, L. L., Lazcano, E., Papenfuss, M. R., Abrahamsen, M., Salmeron, J., Anic, G. M., Rollison, D. E., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62342-2 · Cited by 500
Self-citationQuinn, G. P., Sanchez, J. A., Sutton, S. K., Vadaparampil, S. T., Nguyen, G. T., Green, B. L., Kanetsky, P. A., & Schabath, M. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21288 · Cited by 479
Epithelial Cell Responses to Infection with Human Papillomavirus
Stanley, M. A. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05028-11 · Cited by 473
Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., Porras, C., Schiffman, M., Rodriguez, A. C., Solomon, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068329 · Cited by 473
Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches
Apalla, Z., Nashan, D., Weller, R. B., & Castellsagué, X. (2017) · Dermatology and Therapy · doi:10.1007/s13555-016-0165-y · Cited by 465
Systematic review of the incidence and prevalence of genital warts
Patel, H., Wagner, M., Singhal, P., & Kothari, S. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-39 · Cited by 428
Human Papillomavirus Vaccines: An Updated Review
Cheng, L., Wang, Y., & Du, J. (2020) · Vaccines · doi:10.3390/vaccines8030391 · Cited by 329
Understanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 293
Epidemiology and Clinical Aspects of HPV in Head and Neck Cancers
Chaturvedi, A. K. (2012) · Head and Neck Pathology · doi:10.1007/s12105-012-0377-0 · Cited by 274
The role of HPV in head and neck cancer and review of the HPV vaccine
D'Souza, G., & Dempsey, A. (2011) · Preventive Medicine · doi:10.1016/j.ypmed.2011.08.001 · Cited by 267
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
Kamolratanakul, S., & Pitisuttithum, P. (2021) · Vaccines · doi:10.3390/vaccines9121413 · Cited by 263
Tota, J. E., Chevarie-Davis, M., Richardson, L. A., deVries, M., & Franco, E. L. (2011) · Preventive Medicine · doi:10.1016/j.ypmed.2011.08.017 · Cited by 261
Wang, W., Ma, Y., Wang, X., Zou, H., Zhao, F., Wang, S., Zhang, S., Zhao, Y., Marley, G., & Ma, W. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.04.010 · Cited by 54
Metadata
- Authors
- Giuliano, A. R., Palefsky, J. M., Goldstone, S., Moreira, E. D., Penny, M. E., Aranda, C., Vardas, E., Moi, H., Jessen, H., Hillman, R., Chang, Y.-H., Ferris, D., Rouleau, D., Bryan, J., Marshall, J. B., Vuocolo, S., Barr, E., Radley, D., Haupt, R. M., & Guris, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-02-03
- Volume
- 364
- Issue
- 5
- Pages
- 401-411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2130505310
- Cited by
- 1,146
- References
- 14
- FWCI
- 79.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.